Dia: 13 de novembro de 2021

Fechar ou não fechar? AAE

Beto Matos-Souza
Commercially available, CE-mark approved devices. A1) WATCHMAN (Boston Scientific). A2) WaveCrest (Biosense Webster). B1) Amulet (Abbott Vascular). B2) AMPLATZER Cardiac Plug (Abbott Vascular). B3) Ultraseal LAA Occluder (Cardia). B4) LAmbre (Lifetech). C1) LARIAT (SentreHEART).

https://doi.org/10.1093/europace/euz258

Indication for LAAO device implantation will be discussed for the following five clinical situations:

  • Patients with non-valvular AF who are eligible for chronic long-term OAC
  • Patients with a contraindication for OAC
  • Patients with an elevated bleeding risk under chronic OAC
  • Non-compliant patients (unwilling or unable to take OAC)
  • Specific subgroups:
    • OAC not efficient (“stroke on OAC”)
    • Electrically isolated left atrial appendage post catheter ablation
    • Combination of AF ablation and LAA occluder implantation
    • LAA closure for “primary primary” prevention

Apêndice dispensável ou não?

Beto Matos-Souza

https://doi.org/10.1161/circulationaha.116.021952

Revisão de cirurgias, onde é fácil excluir o AAE, não demonstrou vantagem.

Embolização não é simples de evitar

Beto Matos-Souza

https://academic.oup.com/ehjcr/article/4/4/1/5869483